The U.S. weight-loss drug market is poised for a significant shift as the Trump administration unveiled a groundbreaking agreement with pharmaceutical giants Eli Lilly (LLY) and Novo Nordisk (NVO). The deal will see their popular weight-management medications sold at deep discounts through a new national online platform, “TrumpRx,” potentially dramatically lowering costs for consumers.
The initiative, announced in early November, specifically targets two pure weight-loss GLP-1 drugs: Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. This move aims to make these treatments more accessible, though its ultimate impact on the drugmakers’ profitability and stock performance remains a key question for investors.
The weight-loss drug market has been expanding rapidly. Once a relatively obscure Danish company, Novo Nordisk has gained widespread recognition following Wegovy’s approval. Meanwhile, Eli Lilly’s Zepbound has seen explosive sales growth, skyrocketing from $517 million in its first full quarter after Q1 2024 approval to nearly $3.6 billion in Q3 2025.
This commercial boom is underpinned by surging demand. A recent Gallup survey shows the proportion of U.S. adults who report having used injectable weight-loss drugs more than doubled, jumping from 5.8% in Q1 2024 to 12.4% in Q2-Q3 2025.
Currently, the high list prices pose a substantial barrier. A 28-day supply of Wegovy is priced around $1,349, with a similar supply of Zepbound costing over $1,250. While insurance and manufacturer savings programs can reduce out-of-pocket costs for some, affordability remains a critical issue for many.
The White House announcement detailed substantial price reductions through the TrumpRx platform. The monthly cost for Wegovy and its sister diabetes drug Ozempic is set to drop to $350. Zepbound and Lilly’s investigational drug orforglipron (if approved) will have an average price of $346 per month. For Medicare enrollees, the price will be even lower, standardized at $245 per month with a co-pay of just $50.
This targeted price-cutting strategy is framed as a step toward “democratizing pharmaceutical weight loss,” theoretically enabling broader access, particularly for middle- and low-income patients. However, analysts caution that while volume may increase, the companies’ profit margins are likely to compress significantly due to the steep discounts.
Further uncertainty stems from policy execution risks. The Trump administration’s recent history of volatile tariff policies has raised concerns that the TrumpRx platform could face a similarly unpredictable fate, including the potential for the project to be scrapped entirely.
Financial advisors suggest investors closely monitor the companies’ upcoming quarterly reports for any revisions to financial guidance and changes in analyst ratings based on the TrumpRx rollout. However, with the platform still in the planning stages and key questions about the balance between sales volume and profit remaining unanswered, experts advise against making investment decisions based solely on this agreement.
The long-term benefits for Lilly and Novo Nordisk—whether a net positive or negative—are yet to be determined.
